The study’s goal was to find out if PCSK9 levels in tumor tissue could help predict how well advanced non-small cell lung cancer (NSCLC) would respond to anti-PD-1 treatment and if the PCSK9 inhibitor and anti-CD137 agonist could work together to fight tumors. The gene discussed is TNFRSF9; the disease is non-small cell lung carcinoma.